How LAVERDIA-CA1 (verdinexor) Helps Dogs with Lymphoma

Four features that make LAVERDIA-CA1 treatment different than other cancer treatments.

November 19, 2021
3 min read

Lymphoma is one of the most common cancers diagnosed in dogs. Anivive’s LAVERDIATM-CA1 (verdinexor) treats lymphoma in a unique way.

Novel Targeted Mechanism

LAVERDIA-CA1 is a new conditionally approved drug for treating lymphoma in dogs. LAVERDIA-CA1 works by specifically targeting activity against cancer cells while sparing healthy cells. Cells have a protein called XPO1 that is responsible for carrying important materials in and out of the core of the cell nucleus. Many of these materials help regulate cell growth, but only when they are inside the nucleus. In cancer cells, XPO1 takes too much of the important growth regulator out of the nucleus, allowing cancer cells to grow and spread. LAVERDIA-CA1 targets and blocks XPO1. When LAVERDIA-CA1 binds to XPO1 it can no longer carry the important growth regulators and tumor suppressor proteins out of the nucleus. These materials accumulate in the nucleus resulting in cancer cell death. The most common adverse reactions seen with LAVERDIA-CA1 include: anorexia, vomiting, diarrhea, weight loss, and lethargy.

At Home Treatment

LAVERDIA-CA1 is the first targeted treatment for canine lymphoma in a tablet form. The oral administration of LAVERDIA-CA1 enables dogs to receive treatment from the comfort of home, rather than having to receive injectable treatments at the veterinary hospital.

Developed Specifically for Dogs

Most chemotherapy treatments administered to pets were actually developed for humans. Many cancer-fighting drugs, including the ones used in the CHOP protocol, have proven effective in both people and pets. The selective inhibitor of nuclear export (SINE) technology in LAVERDIA-CA1 is also being used in breakthrough human drugs, but LAVERDIA-CA1 was developed specifically for the special needs of dogs.


From the beginning, Anivive planned to develop and manufacture LAVERDIA-CA1 efficiently and cost effectively. We are passing the cost savings on to veterinarians and pet owners in hopes of increasing the number of pet owners that find it possible to choose a treatment option that best fits their dog’s needs.

Please consult with your veterinarian for further information about LAVERDIA-CA1 (verdinexor.)